关于冠状病毒的治疗，这是加拿大BC省最权威机构的发文。

Louise

关于未经证实的治疗COVID-19的联合声明-关于使用未经证实的治疗和药物治疗COVID-19的警告正在代表BC医生和外科医生学院、BC药剂师学院和BC护理专业人员学院发送。 随着COVID-19全球健康大流行继续影响着人们职业和个人生活的几乎每一个方面，卫生专业人员可能知道在线和社交媒体驱动的关于使用抗疟、抗生素和抗病毒疗法治疗COVID-19患者的对话。 虽然所有不列颠哥伦比亚人都希望能很快找到治愈或治疗方法，但重要的是要注意到，此时，COVID-19已被证实的治疗方法并不存在。 这些治疗要求可能包括但不限于下列药物：羟氯喹、氯喹、阿奇霉素、洛哌/利托那韦（卡莱特拉）和秋水仙碱。在最近发布的关于未经证实的COVID-19治疗的立场声明中，BC疾病控制中心指出：“重要的是要了解对病人有潜在的伤害，我们对什么是真正有益的治疗或不有益的治疗的理解有风险，以及在其他疾病状态下失去已知有帮助或必要的治疗的机会。 由于这些原因，不建议在临床试验之外使用未经证实的COVID-19疗法。“公共卫生官员继续强调，涉及COVID-19的情况将在未来几周变得更加严重。 更多的不列颠哥伦比亚人将被感染，可悲的是，更多的人可能死于这种病毒。 这意味着来自病人、其他医护人员，甚至朋友和家人的善意压力，将无疑会增加。卫生专业人员都对他们的病人和他们的职业负有责任，只关注基于证据的护理，而不屈服于病人对现有药物未经证实和潜在危险用途的压力。 对这些未经证实的治疗方法的需求也有其他意想不到的后果。 甚至在COVID-19被世界卫生组织正式宣布为大流行病之前，加拿大就已经面临短缺，在某些情况下，一些药物供应中断。 由于最近的COVID-19索赔，特别是涉及羟氯喹的索赔，需求增加，甚至出现了更严重的短缺。 这给那些需要这种药物治疗其他疾病的患者带来了严重的潜在后果，包括卢普斯和类风湿关节炎。 关于COVID-19的信息正在迅速发展，随着时间的推移，新的建议和证据可能会出现。鉴于卫生专业人员在确保适当分发药物方面发挥的关键作用，所有人都必须协助确保护理决定完全基于现有的最新证据。 这将确保通过这一全球卫生大流行病为病人提供尽可能好的护理。 医生和护士从业人员不应在临床试验的范围内为COVID-19开出这些疗法，如果他们这样做了，药剂师不应该分发它们。 有关COVID-19未经证实的治疗方法的更多信息，请参阅BC疾病控制中心的以下文件：未经证实的COVID-19临床参考组建议：未经证实的COVID-19海蒂M.Oetter，MD注册官和首席执行官学院的医生和外科医生鲍勃中川，BS C（制药公司）。 )、RPEBC、FCSHP、ACPR注册官和BC Cynthia Johansen的首席药剂师学院、MA、MSC注册官和BC护理专业人员学院首席执行官

Joint statement on unproven therapies for COVID-19

This warning on the use of unproven treatments and medications for COVID-19 is being sent on behalf of the College of Physicians and Surgeons of BC, the College of Pharmacists of BC, and the BC College of Nursing Professionals.

As the COVID-19 global health pandemic continues to impact nearly every aspect of peoples’ professional and personal lives, health professionals are likely aware of online and social media-driven conversations about the use of antimalarial, antibiotic and antiviral therapies to treat COVID-19 patients.

Although all British Columbians are hopeful a cure or treatment can be found quickly, it is critical to note that at this time, a proven treatment for COVID-19 does not exist.

These treatment claims may include, but are not limited to, the following drugs: hydroxychloroquine, chloroquine, azithromycin, lopinavir/ritonavir (Kaletra), and colchicine.

In a recently posted position statement on unproven therapies for COVID-19, the BC Centre for Disease Control states: “It is important to understand that there are potential harms to the patient, risks to our understanding of what is truly a beneficial treatment or not, and depleting access to therapies known to be helpful or essential in other disease states. For these reasons, the use of unproven therapies for COVID-19 is not recommended outside clinical trials.”

Public health officials continue to emphasize that the situation involving COVID-19 is going to become even more acute in the coming weeks. More British Columbians will become infected and tragically, more may die from this virus. This means the well-intentioned pressure from patients, fellow health-care workers, and even friends and family to help access these medications, will undoubtedly increase.

Health professionals all have a responsibility to their patients and to their profession to focus only on evidence-based care and not yield to patient pressure around unproven and potentially dangerous uses of existing medications.

There are also other unintended consequences of the demand for these unproven treatments. Even before COVID-19 was formally declared a pandemic by the World Health Organization, Canada was already facing shortages and, in some cases, supply outages of a number of medications. Due to these recent COVID-19 claims involving hydroxychloroquine in particular, there has been a growth in demand and even more acute shortages. This brings serious potential consequences for patients who need this medication for other conditions including Lupus and rheumatoid arthritis.

Information around COVID-19 is rapidly evolving and new recommendations and evidence may become available with time. Given the critical role health professionals play in ensuring the appropriate distribution of medications, all must assist in ensuring that care decisions are based solely on the most current evidence available. This will ensure the best possible care for patients through this global health pandemic.

Physicians and nurse practitioners should not prescribe these therapies for COVID-19 outside the context of a clinical trial, and pharmacists should not dispense them if they do.

For more information on the unproven therapies for COVID-19, see the following BC Centre for Disease Control documents:

Unproven Therapies for COVID-19

Clinical Reference Group Recommendation: Unproven Therapies for COVID-19

Heidi M. Oetter, MD

Registrar and CEO

College of Physicians and Surgeons of BC

Bob Nakagawa, BSc (Pharm.), RPEBC, FCSHP, ACPR

Registrar and CEO

College of Pharmacists of BC

Cynthia Johansen, MA, MSc

Registrar and CEO

BC College of Nursing Professionals